5-hydroxytryptamine receptor 2B

Timeframe	Studies on this Protein(%)	All Drugs %
pre-1990	1 (0.85)	18.7374
1990's	7 (5.93)	18.2507
2000's	40 (33.90)	29.6817
2010's	61 (51.69)	24.3611
2020's	9 (7.63)	2.80

Drug	Taxonomy	Measurement	Average (mM)	Bioassay(s)	Publication(s)
4-iodo-2,5-dimethoxyphenylisopropylamine	Homo sapiens (human)	IC50	0.0032	6	6
4-iodo-2,5-dimethoxyphenylisopropylamine	Homo sapiens (human)	Ki	0.0104	5	5
1-(3-chlorophenyl)piperazine	Homo sapiens (human)	Ki	0.0244	5	5
methylbufotenin	Homo sapiens (human)	Ki	0.0520	1	1
alosetron	Homo sapiens (human)	IC50	0.1000	1	0
alosetron	Homo sapiens (human)	Ki	0.0640	1	0
alpha-methylserotonin	Homo sapiens (human)	Ki	0.0130	2	2
amiodarone	Homo sapiens (human)	IC50	0.9230	1	0
amiodarone	Homo sapiens (human)	Ki	0.5870	1	0
dan 2163	Homo sapiens (human)	Ki	0.3162	1	1
amitriptyline	Homo sapiens (human)	IC50	0.0700	1	0
amitriptyline	Homo sapiens (human)	Ki	0.0450	1	0
amoxapine	Homo sapiens (human)	IC50	0.0100	1	0
amoxapine	Homo sapiens (human)	Ki	0.0066	1	0
astemizole	Homo sapiens (human)	IC50	0.0120	1	0
astemizole	Homo sapiens (human)	Ki	0.0075	1	0
azelastine	Homo sapiens (human)	Ki	0.0200	1	1
benzbromarone	Homo sapiens (human)	IC50	1.8040	1	0
benzbromarone	Homo sapiens (human)	Ki	1.1480	1	0
bithionol	Homo sapiens (human)	IC50	6.7890	1	0
bithionol	Homo sapiens (human)	Ki	4.3200	1	0
buspirone	Homo sapiens (human)	IC50	0.7500	1	0
buspirone	Homo sapiens (human)	Ki	0.4770	1	0
verapamil	Homo sapiens (human)	IC50	0.1650	1	0
verapamil	Homo sapiens (human)	Ki	0.1050	1	0
carvedilol	Homo sapiens (human)	IC50	0.0230	1	0
carvedilol	Homo sapiens (human)	Ki	0.0150	1	0
chloroxylenol	Homo sapiens (human)	IC50	1.8560	1	0
chloroxylenol	Homo sapiens (human)	Ki	1.1810	1	0
chlorpromazine	Homo sapiens (human)	IC50	0.1260	1	0
chlorpromazine	Homo sapiens (human)	Ki	0.0573	3	2
cisapride	Homo sapiens (human)	IC50	0.0407	3	2
cisapride	Homo sapiens (human)	Ki	0.0549	2	1
citalopram	Homo sapiens (human)	IC50	1.8390	1	0
citalopram	Homo sapiens (human)	Ki	1.1710	1	0
clomipramine	Homo sapiens (human)	IC50	0.2390	1	0
clomipramine	Homo sapiens (human)	Ki	0.1520	1	0
clotrimazole	Homo sapiens (human)	IC50	11.6040	1	0
clotrimazole	Homo sapiens (human)	Ki	7.3850	1	0
cyproheptadine	Homo sapiens (human)	IC50	0.0094	1	0
cyproheptadine	Homo sapiens (human)	Ki	0.0060	1	0
dicyclomine	Homo sapiens (human)	IC50	1.3010	1	0
dicyclomine	Homo sapiens (human)	Ki	0.8280	1	0
diphenhydramine	Homo sapiens (human)	IC50	1.1180	1	0
diphenhydramine	Homo sapiens (human)	Ki	0.7110	1	0
disulfiram	Homo sapiens (human)	IC50	34.5470	1	0
disulfiram	Homo sapiens (human)	Ki	21.9840	1	0
domperidone	Homo sapiens (human)	IC50	2.6000	1	0
domperidone	Homo sapiens (human)	Ki	1.6550	1	0
doxazosin	Homo sapiens (human)	IC50	0.3680	1	0
doxazosin	Homo sapiens (human)	Ki	0.2340	1	0
doxepin	Homo sapiens (human)	IC50	0.0890	1	0
doxepin	Homo sapiens (human)	Ki	0.0560	1	0
droperidol	Homo sapiens (human)	IC50	1.3420	1	0
droperidol	Homo sapiens (human)	Ki	0.8540	1	0
ebastine	Homo sapiens (human)	IC50	0.3126	1	0
ebastine	Homo sapiens (human)	Ki	0.1989	1	0
econazole	Homo sapiens (human)	IC50	6.8330	1	0
econazole	Homo sapiens (human)	Ki	4.3480	1	0
fendiline	Homo sapiens (human)	Ki	3.2170	1	1
fluphenazine	Homo sapiens (human)	IC50	0.0390	1	0
fluphenazine	Homo sapiens (human)	Ki	0.0250	1	0
fluspirilene	Homo sapiens (human)	Ki	0.1514	1	1
guanfacine	Homo sapiens (human)	IC50	2.0980	1	0
guanfacine	Homo sapiens (human)	Ki	1.3350	1	0
haloperidol	Homo sapiens (human)	IC50	2.0500	1	0
haloperidol	Homo sapiens (human)	Ki	0.6625	2	1
hexachlorophene	Homo sapiens (human)	IC50	5.6947	1	0
hexachlorophene	Homo sapiens (human)	Ki	3.6239	1	0
ketanserin	Homo sapiens (human)	IC50	0.2900	1	1
ketanserin	Homo sapiens (human)	Ki	0.1800	1	1
ketotifen	Homo sapiens (human)	IC50	0.0460	1	0
ketotifen	Homo sapiens (human)	Ki	0.0303	2	1
labetalol	Homo sapiens (human)	IC50	3.0370	1	0
labetalol	Homo sapiens (human)	Ki	1.9330	1	0
loperamide	Homo sapiens (human)	IC50	4.1050	1	0
loperamide	Homo sapiens (human)	Ki	2.6130	1	0
loratadine	Homo sapiens (human)	IC50	0.2450	1	0
loratadine	Homo sapiens (human)	Ki	0.1560	1	0
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	Homo sapiens (human)	IC50	36.7070	1	0
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	Homo sapiens (human)	Ki	23.3590	1	0
maprotiline	Homo sapiens (human)	IC50	0.3360	1	0
maprotiline	Homo sapiens (human)	Ki	0.2140	1	0
mescaline	Homo sapiens (human)	Ki	0.7951	1	1
methapyrilene	Homo sapiens (human)	IC50	0.8430	1	0
methapyrilene	Homo sapiens (human)	Ki	0.5370	1	0
nocodazole	Homo sapiens (human)	IC50	20.1800	1	0
nocodazole	Homo sapiens (human)	Ki	12.8450	1	0
metoclopramide	Homo sapiens (human)	IC50	0.6300	1	0
metoclopramide	Homo sapiens (human)	Ki	0.4010	1	0
mexiletine	Homo sapiens (human)	IC50	1.1380	1	0
mexiletine	Homo sapiens (human)	Ki	0.7240	1	0
mianserin	Homo sapiens (human)	IC50	0.0073	1	0
mianserin	Homo sapiens (human)	Ki	0.0046	1	0
miconazole	Homo sapiens (human)	IC50	5.5450	1	0
miconazole	Homo sapiens (human)	Ki	3.5290	1	0
mitotane	Homo sapiens (human)	IC50	4.8320	1	0
mitotane	Homo sapiens (human)	Ki	3.0750	1	0
nortriptyline	Homo sapiens (human)	IC50	0.1360	1	0
nortriptyline	Homo sapiens (human)	Ki	0.0860	1	0
ondansetron	Homo sapiens (human)	IC50	0.7170	1	0
ondansetron	Homo sapiens (human)	Ki	0.4560	1	0
orphenadrine	Homo sapiens (human)	IC50	3.3910	1	0
orphenadrine	Homo sapiens (human)	Ki	2.1580	1	0
oxybutynin	Homo sapiens (human)	IC50	0.7920	1	0
oxybutynin	Homo sapiens (human)	Ki	0.5040	1	0
oxymetazoline	Homo sapiens (human)	IC50	3.0560	1	0
oxymetazoline	Homo sapiens (human)	Ki	1.9450	1	0
prazosin	Homo sapiens (human)	IC50	4.1180	1	0
prazosin	Homo sapiens (human)	Ki	2.6210	1	0
prochlorperazine	Homo sapiens (human)	IC50	0.1020	1	0
prochlorperazine	Homo sapiens (human)	Ki	0.0650	1	0
promazine	Homo sapiens (human)	IC50	0.3470	1	0
promazine	Homo sapiens (human)	Ki	0.2210	1	0
promethazine	Homo sapiens (human)	IC50	0.0680	1	0
promethazine	Homo sapiens (human)	Ki	0.0430	1	0
propafenone	Homo sapiens (human)	IC50	0.0920	1	0
propafenone	Homo sapiens (human)	Ki	0.0580	1	0
propofol	Homo sapiens (human)	IC50	5.4990	1	0
propofol	Homo sapiens (human)	Ki	3.4990	1	0
propranolol	Homo sapiens (human)	IC50	2.6769	2	1
propranolol	Homo sapiens (human)	Ki	0.2180	1	0
psilocin	Homo sapiens (human)	IC50	0.0011	1	1
pyrilamine	Homo sapiens (human)	IC50	2.7880	1	0
pyrilamine	Homo sapiens (human)	Ki	1.7740	1	0
quetiapine	Homo sapiens (human)	IC50	0.2135	1	0
quetiapine	Homo sapiens (human)	Ki	0.2024	3	2
raloxifene	Homo sapiens (human)	IC50	0.3550	1	0
raloxifene	Homo sapiens (human)	Ki	0.1475	2	1
risperidone	Homo sapiens (human)	IC50	0.0230	1	0
risperidone	Homo sapiens (human)	Ki	0.0175	2	1
ritanserin	Homo sapiens (human)	IC50	0.0025	1	3
sb 206553	Homo sapiens (human)	Ki	0.0173	6	7
sulconazole	Homo sapiens (human)	IC50	3.0200	1	0
sulconazole	Homo sapiens (human)	Ki	1.9220	1	0
terfenadine	Homo sapiens (human)	IC50	0.0480	1	0
terfenadine	Homo sapiens (human)	Ki	0.0300	1	0
thioridazine	Homo sapiens (human)	IC50	0.1290	1	0
thioridazine	Homo sapiens (human)	Ki	0.0820	1	0
tolnaftate	Homo sapiens (human)	IC50	2.0070	1	0
tolnaftate	Homo sapiens (human)	Ki	1.2770	1	0
trazodone	Homo sapiens (human)	IC50	0.1070	1	0
trazodone	Homo sapiens (human)	Ki	0.0680	1	0
troglitazone	Homo sapiens (human)	IC50	1.3120	1	0
troglitazone	Homo sapiens (human)	Ki	0.8350	1	0
lysergic acid diethylamide	Homo sapiens (human)	Ki	0.0300	1	1
phentolamine	Homo sapiens (human)	IC50	3.8070	1	0
phentolamine	Homo sapiens (human)	Ki	2.4220	1	0
estrone	Homo sapiens (human)	IC50	13.6300	1	0
estrone	Homo sapiens (human)	Ki	8.6760	1	0
2-acetylaminofluorene	Homo sapiens (human)	IC50	3.1700	1	0
2-acetylaminofluorene	Homo sapiens (human)	Ki	2.0170	1	0
mepazine	Homo sapiens (human)	IC50	0.5140	1	0
mepazine	Homo sapiens (human)	Ki	0.3270	1	0
n,n-dimethyltryptamine	Homo sapiens (human)	Ki	0.1010	1	1
n,n'-diphenyl-4-phenylenediamine	Homo sapiens (human)	IC50	0.1420	1	0
n,n'-diphenyl-4-phenylenediamine	Homo sapiens (human)	Ki	0.0900	1	0
cyclizine	Homo sapiens (human)	IC50	0.3730	1	0
cyclizine	Homo sapiens (human)	Ki	0.2380	1	0
ergotamine	Homo sapiens (human)	IC50	0.0035	1	0
ergotamine	Homo sapiens (human)	Ki	0.0022	1	0
methylergonovine	Homo sapiens (human)	IC50	0.0015	1	0
methylergonovine	Homo sapiens (human)	Ki	0.0009	2	1
sterogenol	Homo sapiens (human)	IC50	5.6900	1	0
sterogenol	Homo sapiens (human)	Ki	3.6210	1	0
yohimbine	Homo sapiens (human)	IC50	0.0740	1	0
yohimbine	Homo sapiens (human)	Ki	0.0470	1	0
indopan	Homo sapiens (human)	Ki	10.0000	1	1
methysergide	Homo sapiens (human)	IC50	0.0006	1	0
methysergide	Homo sapiens (human)	Ki	0.0052	2	2
dihydroergotamine	Homo sapiens (human)	IC50	0.0068	1	0
dihydroergotamine	Homo sapiens (human)	Ki	0.0043	1	0
dimenhydrinate	Homo sapiens (human)	IC50	1.7240	1	0
dimenhydrinate	Homo sapiens (human)	Ki	1.0970	1	0
1-naphthylisothiocyanate	Homo sapiens (human)	IC50	25.1580	1	0
1-naphthylisothiocyanate	Homo sapiens (human)	Ki	16.0090	1	0
Berberine chloride (TN)	Homo sapiens (human)	IC50	3.4370	1	0
Berberine chloride (TN)	Homo sapiens (human)	Ki	2.1870	1	0
n-methyllaurotetanine	Homo sapiens (human)	Ki	0.3230	1	1
glaucine	Homo sapiens (human)	Ki	0.1190	1	1
dexpropranolol	Homo sapiens (human)	IC50	0.4380	1	0
dexpropranolol	Homo sapiens (human)	Ki	0.2790	1	0
camptothecin	Homo sapiens (human)	IC50	0.9700	1	0
camptothecin	Homo sapiens (human)	Ki	0.6170	1	0
clemastine	Homo sapiens (human)	IC50	0.0360	1	0
clemastine	Homo sapiens (human)	Ki	0.0230	1	0
pizotyline	Homo sapiens (human)	Ki	0.0020	1	1
metergoline	Homo sapiens (human)	IC50	0.0004	1	0
metergoline	Homo sapiens (human)	Ki	0.0003	1	0
lisuride	Homo sapiens (human)	IC50	0.0051	1	0
lisuride	Homo sapiens (human)	Ki	0.0032	1	0
bromocriptine	Homo sapiens (human)	IC50	0.0083	1	0
bromocriptine	Homo sapiens (human)	Ki	0.0053	1	0
penfluridol	Homo sapiens (human)	Ki	0.1840	1	1
5-methoxy-alpha-methyltryptamine	Homo sapiens (human)	Ki	0.0078	2	2
6-fluoromelatonin	Homo sapiens (human)	Ki	2.4950	1	1
bopindolol	Homo sapiens (human)	IC50	1.5230	1	0
bopindolol	Homo sapiens (human)	Ki	0.9690	1	0
pergolide	Homo sapiens (human)	IC50	0.0760	1	0
pergolide	Homo sapiens (human)	Ki	0.0490	1	0
cabergoline	Homo sapiens (human)	Ki	0.0014	1	1
aripiprazole	Homo sapiens (human)	Ki	0.0024	3	3
ziprasidone	Homo sapiens (human)	Ki	0.0016	1	1
sertraline	Homo sapiens (human)	IC50	3.3935	1	0
sertraline	Homo sapiens (human)	Ki	2.1595	1	0
mesulergine	Homo sapiens (human)	IC50	0.0052	1	1
mesulergine	Homo sapiens (human)	Ki	0.0028	1	1
adrenoglomerulotropin	Homo sapiens (human)	Ki	0.4910	1	1
ergocornine	Homo sapiens (human)	IC50	0.0110	1	0
ergocornine	Homo sapiens (human)	Ki	0.0069	1	0
u 74006f	Homo sapiens (human)	IC50	18.5070	1	0
u 74006f	Homo sapiens (human)	Ki	11.7770	1	0
way 100635	Homo sapiens (human)	Ki	0.0240	1	1
10-hydroxycarbamazepine	Homo sapiens (human)	Ki	10.0000	1	1
mosapride	Homo sapiens (human)	IC50	0.2959	1	0
mosapride	Homo sapiens (human)	Ki	0.1883	1	0
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine	Homo sapiens (human)	Ki	1.0800	2	2
desloratadine	Homo sapiens (human)	IC50	0.0430	1	0
desloratadine	Homo sapiens (human)	Ki	0.0280	1	0
sb 200646	Homo sapiens (human)	Ki	0.0210	1	1
sc 53116	Homo sapiens (human)	IC50	10.0000	1	1
sc 53116	Homo sapiens (human)	Ki	10.0000	1	1
alpha-ergocryptine	Homo sapiens (human)	IC50	0.0130	1	0
alpha-ergocryptine	Homo sapiens (human)	Ki	0.0082	1	0
n-demethyllysergic acid diethylamide	Homo sapiens (human)	IC50	0.0540	1	1
nantenine, (+-)-isomer	Homo sapiens (human)	Ki	0.5430	2	2
maduramicin	Homo sapiens (human)	IC50	0.0330	1	0
maduramicin	Homo sapiens (human)	Ki	0.0210	1	0
rs 127445	Homo sapiens (human)	IC50	0.0098	2	2
rs 127445	Homo sapiens (human)	Ki	0.0003	1	1
sorafenib	Homo sapiens (human)	Ki	0.0560	1	1
estradiol 3-benzoate	Homo sapiens (human)	IC50	11.5650	1	0
estradiol 3-benzoate	Homo sapiens (human)	Ki	7.3590	1	0
sb 221284	Homo sapiens (human)	Ki	0.0126	2	2
sb 228357	Homo sapiens (human)	Ki	0.0100	1	1
sb 243213	Homo sapiens (human)	Ki	0.1000	3	3
ergonovine	Homo sapiens (human)	IC50	0.0041	1	0
ergonovine	Homo sapiens (human)	Ki	0.0026	1	0
dihydroergocristine monomesylate	Homo sapiens (human)	IC50	0.0066	1	0
dihydroergocristine monomesylate	Homo sapiens (human)	Ki	0.0042	1	0
tretinoin	Homo sapiens (human)	IC50	0.3580	1	0
tretinoin	Homo sapiens (human)	Ki	0.2280	1	0
diethylstilbestrol	Homo sapiens (human)	IC50	3.1400	1	0
diethylstilbestrol	Homo sapiens (human)	Ki	1.9980	1	0
aclarubicin	Homo sapiens (human)	IC50	1.1060	1	0
aclarubicin	Homo sapiens (human)	Ki	0.7040	1	0
(1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol	Homo sapiens (human)	IC50	0.9390	1	0
(1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol	Homo sapiens (human)	Ki	0.5975	1	0
doxepin hydrochloride	Homo sapiens (human)	Ki	0.0253	1	1
flunarizine	Homo sapiens (human)	IC50	1.0880	1	0
flunarizine	Homo sapiens (human)	Ki	0.6920	1	0
benztropine	Homo sapiens (human)	IC50	0.2000	1	0
benztropine	Homo sapiens (human)	Ki	0.1270	1	0
cinnarizine	Homo sapiens (human)	IC50	0.7310	1	0
cinnarizine	Homo sapiens (human)	Ki	0.4650	1	0
enclomiphene	Homo sapiens (human)	IC50	1.3630	1	0
enclomiphene	Homo sapiens (human)	Ki	0.8670	1	0
tamoxifen	Homo sapiens (human)	IC50	2.0840	1	0
tamoxifen	Homo sapiens (human)	Ki	1.3260	1	0
dapiprazole	Homo sapiens (human)	IC50	1.0560	1	0
dapiprazole	Homo sapiens (human)	Ki	0.6720	1	0
mitragynine	Homo sapiens (human)	Ki	1.2600	1	1
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide	Homo sapiens (human)	Ki	2.7700	1	1
paynantheine	Homo sapiens (human)	Ki	0.0516	2	2
bp 897	Homo sapiens (human)	Ki	0.5710	3	3
ym348	Homo sapiens (human)	Ki	0.0025	1	1
ro 60-0175	Homo sapiens (human)	Ki	0.0051	2	2
4-[[(4-methylphenyl)sulfonylamino]methyl]-N-[2-[(phenylmethyl)-propan-2-ylamino]ethyl]benzamide	Homo sapiens (human)	Ki	1.0000	1	1
sb 242084	Homo sapiens (human)	Ki	0.1000	4	4
bw 723c86	Homo sapiens (human)	IC50	0.0811	1	0
bw 723c86	Homo sapiens (human)	Ki	0.0516	1	0
sb 408124	Homo sapiens (human)	Ki	0.3200	1	1
montelukast	Homo sapiens (human)	IC50	6.2560	1	0
montelukast	Homo sapiens (human)	Ki	3.9810	1	0
methysergide maleate	Homo sapiens (human)	Ki	0.0019	1	1
isotretinoin	Homo sapiens (human)	IC50	0.8480	1	0
isotretinoin	Homo sapiens (human)	Ki	0.5400	1	0
ly 344864	Homo sapiens (human)	Ki	0.5000	1	1
l 745870	Homo sapiens (human)	Ki	0.6000	2	2
mdl 100907	Homo sapiens (human)	Ki	1.2589	1	1
sb 258719	Homo sapiens (human)	Ki	5.0119	1	1
sb 271046	Homo sapiens (human)	Ki	3.9811	1	1
oxiconazole	Homo sapiens (human)	IC50	4.6064	1	0
oxiconazole	Homo sapiens (human)	Ki	2.9314	1	0
guanabenz	Homo sapiens (human)	IC50	0.0970	1	0
guanabenz	Homo sapiens (human)	Ki	0.0620	1	0
tg4-155	Homo sapiens (human)	IC50	2.6000	1	1
sb 269970	Homo sapiens (human)	Ki	6.6683	3	3
sb 334867-a	Homo sapiens (human)	Ki	3.9811	1	1
n-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide	Homo sapiens (human)	Ki	3.9811	1	1
4-iodo-2,5-dimethoxyphenylisopropylamine, (r)-isomer	Homo sapiens (human)	Ki	0.0127	3	3
sb258741	Homo sapiens (human)	Ki	2.5119	1	1
slv 313	Homo sapiens (human)	Ki	0.0126	1	1
fauc 346	Homo sapiens (human)	Ki	0.3500	1	1
pnu 96415e	Homo sapiens (human)	Ki	0.0696	1	1
st 1936	Homo sapiens (human)	Ki	0.2450	1	1
n-(4-((4-(dimethylamino)quinazolin-2-yl)amino)cyclohexyl)-3,4-difluorobenzamide hydrochloride	Homo sapiens (human)	IC50	0.0798	2	2
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride	Homo sapiens (human)	Ki	1.0000	1	1
1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene	Homo sapiens (human)	Ki	0.2400	1	1
sb-656104-a	Homo sapiens (human)	Ki	0.0912	1	1
pimavanserin	Homo sapiens (human)	IC50	0.0464	1	2
way 181187	Homo sapiens (human)	Ki	0.4298	2	4
2-(4-iodo-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)ethanamine	Homo sapiens (human)	Ki	0.0023	1	1
fauc 365	Homo sapiens (human)	Ki	2.0000	1	1
sb-649915	Homo sapiens (human)	Ki	1.5849	1	1
meridianin a	Homo sapiens (human)	Ki	0.1500	1	1
sb 215505	Homo sapiens (human)	IC50	0.0385	2	2
mrs 3558	Homo sapiens (human)	IC50	3.2600	1	1
naluzotan	Homo sapiens (human)	Ki	5.0000	1	1
prx 08066	Homo sapiens (human)	IC50	0.1368	2	2
prx 08066	Homo sapiens (human)	Ki	0.0034	1	1
5-hydroxy-2-(2-phenylethyl)chromone	Homo sapiens (human)	IC50	8.9125	1	1
5-hydroxy-2-(2-phenylethyl)chromone	Homo sapiens (human)	Ki	2.4547	1	1
col-144	Homo sapiens (human)	Ki	0.5930	1	1
lorcaserin	Homo sapiens (human)	Ki	0.1517	5	5
td-5108	Homo sapiens (human)	Ki	0.0020	1	1
brexpiprazole	Homo sapiens (human)	Ki	0.0004	1	1
mitragynine	Homo sapiens (human)	Ki	0.0655	2	2
sp 203	Homo sapiens (human)	Ki	10.0000	1	1
lu aa33810	Homo sapiens (human)	Ki	0.2450	1	1
pf 04457845	Homo sapiens (human)	Ki	1.3437	1	0
e-52862	Homo sapiens (human)	IC50	4.7000	1	1
e-52862	Homo sapiens (human)	Ki	0.3280	1	1
nitd 609	Homo sapiens (human)	IC50	10.0000	1	1
skepinone-l	Homo sapiens (human)	Ki	0.1724	1	0
n,n-diallyl-5-methoxytryptamine	Homo sapiens (human)	Ki	2.5311	2	4
ogerin	Homo sapiens (human)	Ki	0.4964	1	0
tg6-10-1	Homo sapiens (human)	IC50	7.5000	1	1
clozapine	Homo sapiens (human)	IC50	0.0810	2	3
clozapine	Homo sapiens (human)	Ki	0.0051	3	2
olanzapine	Homo sapiens (human)	IC50	0.0570	1	0
olanzapine	Homo sapiens (human)	Ki	0.0212	2	1
tegaserod	Homo sapiens (human)	Ki	0.0020	1	1
methylaplysinopsin	Homo sapiens (human)	Ki	4.5540	1	1
aplysinopsin	Homo sapiens (human)	Ki	4.4490	1	1

Drug	Taxonomy	Measurement	Average (mM)	Bioassay(s)	Publication(s)
1-(3-chlorophenyl)piperazine	Homo sapiens (human)	EC50	0.3545	9	9
methylbufotenin	Homo sapiens (human)	Kd	0.0794	1	1
propranolol	Homo sapiens (human)	EC50	5.0119	1	1
psilocin	Homo sapiens (human)	EC50	0.0580	1	1
sb 206553	Homo sapiens (human)	EC50	0.0130	1	1
mecoprop	Homo sapiens (human)	EC50	0.0930	1	1
methylergonovine	Homo sapiens (human)	EC50	0.0214	1	1
indopan	Homo sapiens (human)	EC50	0.0758	1	2
psilocybin	Homo sapiens (human)	EC50	0.0740	1	1
cabergoline	Homo sapiens (human)	EC50	0.0130	1	1
Serotonin hydrochloride	Homo sapiens (human)	EC50	0.0004	1	2
5-hydroxytryptophan	Homo sapiens (human)	EC50	0.0011	1	2
ym348	Homo sapiens (human)	EC50	0.0032	1	1
ro 60-0175	Homo sapiens (human)	EC50	0.0031	4	4
norfenfluramine	Homo sapiens (human)	EC50	0.0158	1	1
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine	Homo sapiens (human)	EC50	0.0653	1	1
lorcaserin	Homo sapiens (human)	EC50	0.5083	10	14
pf 3246799	Homo sapiens (human)	EC50	10.0000	1	1
n,n-diallyl-5-methoxytryptamine	Homo sapiens (human)	EC50	0.0055	1	2
clozapine	Homo sapiens (human)	EC50	0.0200	1	0

Drug	Taxonomy	Measurement	Average (mM)	Bioassay(s)	Publication(s)
ketanserin	Homo sapiens (human)	Kb	1.9800	1	1
nuciferine	Homo sapiens (human)	Kb	0.0310	1	1
metergoline	Homo sapiens (human)	Activity	0.0026	1	1
roemerine	Homo sapiens (human)	Kb	0.0840	1	1
yil 781	Homo sapiens (human)	Activity	1.0000	1	1

Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT
Journal of medicinal chemistry, , 07-27, Volume: 60, Issue:14, 2017

Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT
Bioorganic & medicinal chemistry letters, , 12-15, Volume: 26, Issue:24, 2016

Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 20, Issue:3, 2010

Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.
Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 19, Issue:17, 2009

Design and synthesis of pyridazinone-based 5-HT(2C) agonists.
Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 19, Issue:19, 2009

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
Journal of medicinal chemistry, , Jan-24, Volume: 51, Issue:2, 2008

Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.
Journal of medicinal chemistry, , Mar-22, Volume: 50, Issue:6, 2007

Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.
Bioorganic & medicinal chemistry letters, , Volume: 16, Issue:3, 2006

Indoline derivatives as 5-HT(2C) receptor agonists.
Bioorganic & medicinal chemistry letters, , May-03, Volume: 14, Issue:9, 2004

1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Journal of medicinal chemistry, , Jan-12, Volume: 49, Issue:1, 2006

Serotonin receptor binding affinities of several hallucinogenic phenylalkylamine and N,N-dimethyltryptamine analogues.
Journal of medicinal chemistry, , Volume: 21, Issue:8, 1978

[no title available]
,

1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Journal of medicinal chemistry, , Jan-12, Volume: 49, Issue:1, 2006

A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.
Journal of medicinal chemistry, , Sep-11, Volume: 46, Issue:19, 2003

[no title available]
,

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

[no title available]
,

Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H
Bioorganic & medicinal chemistry letters, , 11-01, Volume: 27, Issue:21, 2017

[no title available]
,

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

[no title available]
,

Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 23, Issue:14, 2013

Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.
Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006

Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750.
Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 14, Issue:22, 2004

[no title available]
,

[no title available]
,

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

[no title available]
,

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

[no title available]
,

Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?
Bioorganic & medicinal chemistry letters, , May-21, Volume: 11, Issue:10, 2001

[no title available]
,

[no title available]
,

Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT
MedChemComm, , Mar-01, Volume: 9, Issue:3, 2018

Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 23, Issue:6, 2013

Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

[no title available]
,

[no title available]
,

Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
Journal of medicinal chemistry, , Sep-12, Volume: 40, Issue:19, 1997

[no title available]
,

Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.
Journal of medicinal chemistry, , Dec-10, Volume: 58, Issue:23, 2015

[no title available]
,

Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders.
ACS medicinal chemistry letters, , Dec-09, Volume: 12, Issue:12, 2021

SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 15, Issue:20, 2005

[no title available]
,

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?
Bioorganic & medicinal chemistry letters, , May-21, Volume: 11, Issue:10, 2001

[no title available]
,

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

[no title available]
,

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

[no title available]
,

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
The Journal of pharmacology and experimental therapeutics, , Volume: 317, Issue:2, 2006

Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT
Journal of natural products, , 09-23, Volume: 85, Issue:9, 2022

Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D
Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020

Pharmacophore-based tailoring of biphenyl amide derivatives as selective 5-hydroxytryptamine 2B receptor antagonists.
MedChemComm, , Jun-01, Volume: 9, Issue:6, 2018

The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 24, Issue:2, 2014

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.
Journal of medicinal chemistry, , May-07, Volume: 41, Issue:10, 1998

6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.
Journal of medicinal chemistry, , Oct-24, Volume: 40, Issue:22, 1997

[no title available]
,

Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
Journal of medicinal chemistry, , Sep-12, Volume: 45, Issue:19, 2002

[no title available]
,

Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
Journal of medicinal chemistry, , Mar-25, Volume: 42, Issue:6, 1999

[no title available]
,

Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 16, Issue:4, 2008

[no title available]
,

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

[no title available]
,

[no title available]
,

An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013

The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 24, Issue:2, 2014

[no title available]
,

Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT
MedChemComm, , Mar-01, Volume: 9, Issue:3, 2018

[no title available]
,

SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 15, Issue:20, 2005

[no title available]
,

Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors.
Journal of natural products, , Apr-24, Volume: 78, Issue:4, 2015

Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT
Journal of natural products, , 09-23, Volume: 85, Issue:9, 2022

[no title available]
,

Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 21, Issue:24, 2013

Evaluation of [(11)C]metergoline as a PET radiotracer for 5HTR in nonhuman primates.
Bioorganic & medicinal chemistry, , Nov-15, Volume: 18, Issue:22, 2010

[no title available]
,

[no title available]
,

Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity.
Bioorganic & medicinal chemistry letters, , 12-15, Volume: 28, Issue:23-24, 2018

1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Journal of medicinal chemistry, , Jan-12, Volume: 49, Issue:1, 2006

A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.
Journal of medicinal chemistry, , Sep-11, Volume: 46, Issue:19, 2003

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

[no title available]
,

Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism.
ACS medicinal chemistry letters, , Feb-14, Volume: 4, Issue:2, 2013

[no title available]
European journal of medicinal chemistry, , Jan-05, Volume: 227, 2022

Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
Bioorganic & medicinal chemistry, , 08-15, Volume: 24, Issue:16, 2016

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

[no title available]
,

[no title available]
European journal of medicinal chemistry, , Aug-15, Volume: 176, 2019

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

[no title available]
,

Design, synthesis and in vitro evaluation of bridgehead fluoromethyl analogs of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) for the 5-HT(1A) receptor.
European journal of medicinal chemistry, , Volume: 46, Issue:12, 2011

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT
MedChemComm, , Mar-01, Volume: 9, Issue:3, 2018

[no title available]
,

[no title available]
Journal of medicinal chemistry, , 12-22, Volume: 59, Issue:24, 2016

In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.
Journal of medicinal chemistry, , Dec-11, Volume: 57, Issue:23, 2014

[no title available]
,

New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.
Bioorganic & medicinal chemistry letters, , 07-15, Volume: 26, Issue:14, 2016

Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.
Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006

Bridgehead-methyl analog of SC-53116 as a 5-HT4 agonist.
Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 14, Issue:12, 2004

[no title available]
,

Discovery of Highly Potent Serotonin 5-HT
ACS medicinal chemistry letters, , Apr-14, Volume: 13, Issue:4, 2022

Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.
Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 19, Issue:21, 2009

C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.
Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 25, Issue:17, 2015

Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.
Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 20, Issue:2, 2010

[no title available]
,

Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022

A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.
Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009

Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.
Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012

[no title available]
,

Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.
Journal of medicinal chemistry, , Jan-28, Volume: 59, Issue:2, 2016

Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.
Journal of medicinal chemistry, , May-07, Volume: 41, Issue:10, 1998

6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.
Journal of medicinal chemistry, , Oct-24, Volume: 40, Issue:22, 1997

Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.
Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000

A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.
Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 15, Issue:22, 2005

Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.
Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000

1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.
Bioorganic & medicinal chemistry letters, , Aug-21, Volume: 10, Issue:16, 2000

[no title available]
,

Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor-Ligand Interactions.
ACS medicinal chemistry letters, , Oct-11, Volume: 9, Issue:10, 2018

[no title available]
,

Activity of
Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021

[no title available]
Journal of medicinal chemistry, , 12-22, Volume: 59, Issue:24, 2016

Activity of
Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

Fancy bioisosteres: novel paracyclophane derivatives as super-affinity dopamine D3 receptor antagonists.
Journal of medicinal chemistry, , Jun-15, Volume: 49, Issue:12, 2006

Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.
Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002

Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.
Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008

Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 16, Issue:4, 2008

Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
Bioorganic & medicinal chemistry, , Feb-15, Volume: 16, Issue:4, 2008

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
Journal of medicinal chemistry, , Jan-24, Volume: 51, Issue:2, 2008

Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.
Bioorganic & medicinal chemistry letters, , Volume: 16, Issue:3, 2006

Indoline derivatives as 5-HT(2C) receptor agonists.
Bioorganic & medicinal chemistry letters, , May-03, Volume: 14, Issue:9, 2004

Antagonists of the kappa opioid receptor.
Bioorganic & medicinal chemistry letters, , May-01, Volume: 24, Issue:9, 2014

A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.
Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 15, Issue:22, 2005

Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.
Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000

1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.
Bioorganic & medicinal chemistry letters, , Aug-21, Volume: 10, Issue:16, 2000

6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.
Journal of medicinal chemistry, , Oct-24, Volume: 40, Issue:22, 1997

[no title available]
,

Selective orexin receptor antagonists.
Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 23, Issue:17, 2013

[no title available]
,

[no title available]
European journal of medicinal chemistry, , Dec-01, Volume: 183, 2019

[no title available]
,

Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022

Current and novel approaches to the drug treatment of schizophrenia.
Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001

3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor.
Journal of medicinal chemistry, , May-10, Volume: 39, Issue:10, 1996

Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist.
Journal of medicinal chemistry, , Feb-26, Volume: 41, Issue:5, 1998

Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists.
Bioorganic & medicinal chemistry letters, , May-20, Volume: 12, Issue:10, 2002

[no title available]
,

Prostanoid receptor EP2 as a therapeutic target.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

Discovery of G Protein-Biased Antagonists against 5-HT
Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021

Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.
Bioorganic & medicinal chemistry, , 11-15, Volume: 24, Issue:22, 2016

A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000

1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.
Bioorganic & medicinal chemistry letters, , Jul-23, Volume: 11, Issue:14, 2001

Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).
Bioorganic & medicinal chemistry letters, , Jan-08, Volume: 11, Issue:1, 2001

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
Journal of medicinal chemistry, , Jan-24, Volume: 51, Issue:2, 2008

Activity of
Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021

1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Journal of medicinal chemistry, , Jan-12, Volume: 49, Issue:1, 2006

A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.
Journal of medicinal chemistry, , Sep-11, Volume: 46, Issue:19, 2003

A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).
Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.
Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002

Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.
Journal of medicinal chemistry, , Feb-26, Volume: 58, Issue:4, 2015

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Journal of medicinal chemistry, , Nov-11, Volume: 53, Issue:21, 2010

Therapeutic Potential of 5-HT6 Receptor Agonists.
Journal of medicinal chemistry, , Oct-22, Volume: 58, Issue:20, 2015

Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.
Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 19, Issue:21, 2009

Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
Journal of medicinal chemistry, , Sep-09, Volume: 53, Issue:17, 2010

Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.
Bioorganic & medicinal chemistry, , Apr-01, Volume: 23, Issue:7, 2015

SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties.
Bioorganic & medicinal chemistry letters, , Nov-18, Volume: 12, Issue:22, 2002

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
The Journal of pharmacology and experimental therapeutics, , Volume: 317, Issue:2, 2006

Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.
Journal of medicinal chemistry, , Nov-15, Volume: 50, Issue:23, 2007

Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022

Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.
Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002

3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.
Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 17, Issue:4, 2007

CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.
Bioorganic & medicinal chemistry, , Oct-01, Volume: 19, Issue:19, 2011

A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.
Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009

[no title available]
Journal of medicinal chemistry, , 12-22, Volume: 59, Issue:24, 2016

An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
Journal of medicinal chemistry, , Jun-01, Volume: 49, Issue:11, 2006

Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
Bioorganic & medicinal chemistry, , 04-01, Volume: 27, Issue:7, 2019

A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.
Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009

5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC): a novel non-nitrogenous ligand for 5-HT2B receptor.
Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 24, Issue:6, 2014

Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022

Discovery of a lead series of potent benzodiazepine 5-HT
Bioorganic & medicinal chemistry letters, , 03-01, Volume: 30, Issue:5, 2020

Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT
Journal of medicinal chemistry, , 01-10, Volume: 62, Issue:1, 2019

Identification of fluorinated (R)-(-)-aporphine derivatives as potent and selective ligands at serotonin 5-HT
Bioorganic & medicinal chemistry letters, , 01-15, Volume: 29, Issue:2, 2019

Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT
European journal of medicinal chemistry, , Nov-15, Volume: 182, 2019

Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.
Journal of medicinal chemistry, , 07-27, Volume: 60, Issue:14, 2017

Design and Discovery of Functionally Selective Serotonin 2C (5-HT
Journal of medicinal chemistry, , 11-10, Volume: 59, Issue:21, 2016

Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.
Journal of medicinal chemistry, , Jan-28, Volume: 59, Issue:2, 2016

Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.
Journal of medicinal chemistry, , Feb-26, Volume: 58, Issue:4, 2015

Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.
Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 23, Issue:1, 2013

Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.
Bioorganic & medicinal chemistry letters, , May-01, Volume: 21, Issue:9, 2011

Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.
Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
Journal of medicinal chemistry, , Jan-24, Volume: 51, Issue:2, 2008

Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.
Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 15, Issue:5, 2005

Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 22, Issue:19, 2012

[no title available]
European journal of medicinal chemistry, , Dec-01, Volume: 183, 2019

Activity of
Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021

Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.
Journal of medicinal chemistry, , Jul-12, Volume: 50, Issue:14, 2007

Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.
Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 21, Issue:18, 2011

Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

[no title available]
,

Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.
Journal of medicinal chemistry, , Jun-26, Volume: 57, Issue:12, 2014

Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
Journal of medicinal chemistry, , Oct-11, Volume: 55, Issue:19, 2012

Spiroindolones, a potent compound class for the treatment of malaria.
Science (New York, N.Y.), , Sep-03, Volume: 329, Issue:5996, 2010

[no title available]
,

Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 26, Issue:3, 2016

An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013

[no title available]
,

Prostanoid receptor EP2 as a therapeutic target.
Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
The Journal of pharmacology and experimental therapeutics, , Volume: 317, Issue:2, 2006

Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?
Bioorganic & medicinal chemistry letters, , May-21, Volume: 11, Issue:10, 2001

[no title available]
,

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007

[no title available]
,

Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 23, Issue:14, 2013

In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.
Bioorganic & medicinal chemistry, , Nov-15, Volume: 21, Issue:22, 2013

Target	Category	Definition
Gq/11-coupled serotonin receptor activity	molecular function	Combining with serotonin and transmitting the signal across the membrane by activation of the Gq/11 subunit of an associated cytoplasmic heterotrimeric G protein complex. The Gq/11 subunit subsequently activates phospholipase C and results in an increase in inositol triphosphate (IP3) levels. [GOC:bf, GOC:mah, PMID:18571247, PMID:18703043]
G-protein alpha-subunit binding	molecular function	Binding to a G-protein alpha subunit. The alpha subunit binds a guanine nucleotide. [GOC:hjd]
G protein-coupled serotonin receptor activity	molecular function	Combining with the biogenic amine serotonin and transmitting the signal across the membrane by activating an associated G-protein. Serotonin (5-hydroxytryptamine) is a neurotransmitter and hormone found in vertebrates and invertebrates. [GOC:ai]
GTPase activator activity	molecular function	Binds to and increases the activity of a GTPase, an enzyme that catalyzes the hydrolysis of GTP. [GOC:mah]
protein binding	molecular function	Binding to a protein. [GOC:go_curators]
serotonin binding	molecular function	Binding to serotonin (5-hydroxytryptamine), a monoamine neurotransmitter occurring in the peripheral and central nervous systems, also having hormonal properties. [GOC:ai]
neurotransmitter receptor activity	molecular function	Combining with a neurotransmitter and transmitting the signal to initiate a change in cell activity. [GOC:jl, GOC:signaling]

Target	Category	Definition
nucleoplasm	cellular component	That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653]
cytoplasm	cellular component	The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684]
plasma membrane	cellular component	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363]
synapse	cellular component	The junction between an axon of one neuron and a dendrite of another neuron, a muscle fiber or a glial cell. As the axon approaches the synapse it enlarges into a specialized structure, the presynaptic terminal bouton, which contains mitochondria and synaptic vesicles. At the tip of the terminal bouton is the presynaptic membrane; facing it, and separated from it by a minute cleft (the synaptic cleft) is a specialized area of membrane on the receiving cell, known as the postsynaptic membrane. In response to the arrival of nerve impulses, the presynaptic terminal bouton secretes molecules of neurotransmitters into the synaptic cleft. These diffuse across the cleft and transmit the signal to the postsynaptic membrane. [GOC:aruk, ISBN:0198506732, PMID:24619342, PMID:29383328, PMID:31998110]

Target	Category	Definition
dendrite	cellular component	A neuron projection that has a short, tapering, morphology. Dendrites receive and integrate signals from other neurons or from sensory stimuli, and conduct nerve impulses towards the axon or the cell body. In most neurons, the impulse is conveyed from dendrites to axon via the cell body, but in some types of unipolar neuron, the impulse does not travel via the cell body. [GOC:aruk, GOC:bc, GOC:dos, GOC:mah, GOC:nln, ISBN:0198506732]
plasma membrane	cellular component	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363]

Target	Category	Definition
neural crest cell migration	biological process	The characteristic movement of cells from the dorsal ridge of the neural tube to a variety of locations in a vertebrate embryo. [GOC:ascb_2009, GOC:dph, GOC:tb, ISBN:0878932437]
positive regulation of cytokine production	biological process	Any process that activates or increases the frequency, rate or extent of production of a cytokine. [GOC:add, ISBN:0781735149]
positive regulation of endothelial cell proliferation	biological process	Any process that activates or increases the rate or extent of endothelial cell proliferation. [GOC:add]
G protein-coupled receptor internalization	biological process	The process that results in the uptake of a G protein-coupled receptor into an endocytic vesicle. [PMID:8396717]
heart morphogenesis	biological process	The developmental process in which the heart is generated and organized. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood. [GOC:dph, GOC:isa_complete]
cardiac muscle hypertrophy	biological process	The enlargement or overgrowth of all or part of the heart muscle due to an increase in size of cardiac muscle cells without cell division. [GOC:mtg_heart]
intracellular calcium ion homeostasis	biological process	A homeostatic process involved in the maintenance of a steady state level of calcium ions within a cell. [GOC:ceb, GOC:mah]
G protein-coupled receptor signaling pathway	biological process	The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane. [GOC:bf, GOC:mah, PMID:16902576, PMID:24568158, Wikipedia:G_protein-coupled_receptor]
activation of phospholipase C activity	biological process	The initiation of the activity of the inactive enzyme phospolipase C as the result of The series of molecular signals generated as a consequence of a G protein-coupled receptor binding to its physiological ligand. [GOC:dph, GOC:mah, GOC:tb, PMID:8280098]
protein kinase C-activating G protein-coupled receptor signaling pathway	biological process	The series of molecular signals generated as a consequence of a G protein-coupled receptor binding to its physiological ligand, where the pathway proceeds with activation of protein kinase C (PKC). PKC is activated by second messengers including diacylglycerol (DAG). [GOC:mah, GOC:signaling]
phospholipase C-activating serotonin receptor signaling pathway	biological process	A phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by serotonin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:dph, GOC:mah, GOC:signaling, GOC:tb]
positive regulation of cell population proliferation	biological process	Any process that activates or increases the rate or extent of cell proliferation. [GOC:go_curators]
response to xenobiotic stimulus	biological process	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc]
positive regulation of phosphatidylinositol biosynthetic process	biological process	Any process that increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phosphatidylinositol. [GOC:dph, GOC:tb, GOC:vw]
neural crest cell differentiation	biological process	The process in which a relatively unspecialized cell acquires specialized features of a neural crest cell. [GOC:dh, GOC:ef]
intestine smooth muscle contraction	biological process	A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. This process occurs in the intestine. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. The intestine is the section of the alimentary canal from the stomach to the anal canal. It includes the large intestine and small intestine. [GOC:mtg_muscle, MA:0001539, MSH:D007422]
phosphorylation	biological process	The process of introducing a phosphate group into a molecule, usually with the formation of a phosphoric ester, a phosphoric anhydride or a phosphoric amide. [ISBN:0198506732]
calcium-mediated signaling	biological process	Any intracellular signal transduction in which the signal is passed on within the cell via calcium ions. [GOC:signaling]
cGMP-mediated signaling	biological process	An intracellular signaling cassette that starts with production of cyclic GMP (cGMP), and ends with activation of downstream effectors that further transmit the signal within the cell. [GOC:signaling]
vasoconstriction	biological process	A decrease in the diameter of blood vessels, especially arteries, due to constriction of smooth muscle cells that line the vessels, and usually causing an increase in blood pressure. [GOC:pr, ISBN:0192800752]
negative regulation of apoptotic process	biological process	Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. [GOC:jl, GOC:mtg_apoptosis]
positive regulation of canonical NF-kappaB signal transduction	biological process	Any process that activates or increases the frequency, rate or extent of a canonical NF-kappaB signaling cascade. [GOC:jl]
positive regulation of MAP kinase activity	biological process	Any process that activates or increases the frequency, rate or extent of MAP kinase activity. [GOC:dph, GOC:go_curators]
phosphatidylinositol 3-kinase/protein kinase B signal transduction	biological process	An intracellular signaling cassette that starts with phosphatidylinositol 3-kinase (PI3K) activation, production of phosphatidylinositol 3-phosphate (PI3P), activation of PDK1, which recruits and ending with the activation of protein kinase B (PKB, also known as Akt). PI3K is activated by cell surface receptors. Note that PTEN is an inhibitor of the pathway. [PMID:20517722, PMID:22952397]
embryonic morphogenesis	biological process	The process in which anatomical structures are generated and organized during the embryonic phase. The embryonic phase begins with zygote formation. The end of the embryonic phase is organism-specific. For example, it would be at birth for mammals, larval hatching for insects and seed dormancy in plants. [GOC:jid, GOC:mtg_sensu]
regulation of behavior	biological process	Any process that modulates the frequency, rate or extent of behavior, the internally coordinated responses (actions or inactions) of whole living organisms (individuals or groups) to internal or external stimuli. [GOC:go_curators, GOC:pr]
positive regulation of nitric-oxide synthase activity	biological process	Any process that activates or increases the activity of the enzyme nitric-oxide synthase. [GOC:ai]
release of sequestered calcium ion into cytosol	biological process	The process in which calcium ions sequestered in the endoplasmic reticulum, Golgi apparatus or mitochondria are released into the cytosolic compartment. [GOC:dph, GOC:hjd, GOC:mtg_lung, PMID:1814929]
positive regulation of cell division	biological process	Any process that activates or increases the frequency, rate or extent of cell division. [GOC:ai]
ERK1 and ERK2 cascade	biological process	A MAPK cascade containing at least the ERK1 or ERK2 MAP kinases. It starts with the activation of a MAP3K, and the consecutive activation of a MPK2K and of ERK1 or ERK2. The cascade can also contain an additional tier: the upstream MAP4K. The kinases in each tier phosphorylate and activate the kinase in the downstream tier. The ERK1/ERK2 cascade is activated by mitogens, growth factors, G protein-coupled receptors, and results in cellular responses such as cell proliferation, cell differentiation and development. [PMID:20811974, PMID:23125017, PMID:28903453]
positive regulation of ERK1 and ERK2 cascade	biological process	Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. [GOC:mah]
protein kinase C signaling	biological process	A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase C, which occurs as a result of a single trigger reaction or compound. [GOC:BHF, GOC:mah]
cellular response to temperature stimulus	biological process	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a temperature stimulus. [GOC:mah]
G protein-coupled serotonin receptor signaling pathway	biological process	The series of molecular signals generated as a consequence of a G protein-coupled serotonin receptor binding to one of its physiological ligands. [GOC:mah]
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	biological process	A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation or inhibition of a nucleotide cyclase activity and a subsequent change in the concentration of a cyclic nucleotide. [GOC:mah, GOC:signaling, ISBN:0815316194]
serotonin receptor signaling pathway	biological process	The series of molecular signals generated as a consequence of a serotonin receptor binding to one of its physiological ligands. [GOC:mah]
chemical synaptic transmission	biological process	The vesicular release of classical neurotransmitter molecules from a presynapse, across a chemical synapse, the subsequent activation of neurotransmitter receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse. [GOC:jl, MeSH:D009435]

5-hydroxytryptamine receptor 2B

Synonyms

Research

Bioassay Publications (118)

Compounds (222)

Drugs with Inhibition Measurements

Drugs with Activation Measurements

Drugs with Other Measurements

Enables

Located In

Active In

Part Of

Involved In